IP Library Granted Patent US 9,028,879
Granted Patent B2
US 9,028,879 · App. 13/380,940 · Granted May 12, 2015

Chromium complexes as enhancers of brain glucose transporters

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,028,879
App. No.
13/380,940
Granted
May 12, 2015
Kind
B2
Abstract

The embodiments disclosed herein relate to compositions for enhancing brain glucose transporters, such as GLUT1 and GLUT3, and methods of treating and/or preventing diseases or disorders associated with the regulation GLUT1 and GLUT3. Also provided are compositions that include chromium and an agent that targets the brain or the central nervous system. Further provided are improved methods of delivering therapeutic agents that target the brain and/or central nervous system.

Claims (10)

1. A method of enhancing glucose transporters in the brain of a subject in need thereof, comprising:

identifying a subject in need of increased glucose transport in the brain; and

administering to a subject in need thereof an amount of chromium effective to increase the levels of GLUT-1 or GLUT-3 in the brain.

2. The method of claim 1 , wherein the chromium is a chromium complex.

3. The method of claim 1 , wherein the subject is human.

4. The method of claim 3 , wherein the subject has a disease or disorder associated with a decreased level of glucose transporters in the brain.

5. The method of claim 4 , wherein the disease or disorder is selected from the group consisting of: Alzheimer's disease, dementia, mild cognitive impairment (MCI), attention deficit hyperactive disorder (ADHD), Huntington's Disease, epilepsy, and Parkinson's Disease.

6. The method of claim 2 , wherein the chromium complex comprises chromium histidinate.

7. The method of claim 6 , wherein the chromium complex further comprises chromium picolinate.

8. The method of claim 2 , wherein the chromium complex consists essentially of chromium histidinate and chromium picolinate.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2015
From: KOMOROWSKI, JAMES R.
To: JDS THERAPEUTICS LLC
Reel/Frame 035374/0515 →